QURE240719P9000
- 3.00
- 0.000.00%
uniQure NV Newsroom
William Blair Maintains UniQure NV(QURE.US) With Buy Rating
William Blair analyst Sami Corwin maintains $uniQure NV(QURE.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 37.2% and a total average return of -4.6% over the pas
Sector Update: Health Care Stocks Mixed Premarket Monday
Health care stocks were mixed premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was 0.3% higher and the iShares Biotechnology ETF (IBB) was down 0.2% recently. SpringWorks Therapeutics
UniQure: Genezen Will Enter Strategic Supply Agreements for UniQure's Clinical Portfolio and CSL's Comml HEMGENIX Pdt >QURE
UniQure: Genezen Will Enter Strategic Supply Agreements for UniQure's Clinical Portfolio and CSL's Comml HEMGENIX Pdt >QURE
Genezen To Acquire UniQure's Commercial Gene Therapy Manufacturing Operations In Lexington, MA QURE
Genezen To Acquire UniQure's Commercial Gene Therapy Manufacturing Operations In Lexington, MA QURE
UniQure Shares Rise After US FDA Grants Regenerative Medicine Advanced Designation for Huntington's Treatment
uniQure (QURE) shares rose 8% in recent Monday trading after the company obtained the regenerative medicine advanced therapy designation from the US Food and Drug Administration for AMT-130 to treat H
UniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease
~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington's disease ~ ~ Receiving
UniQure N.V. (NASDAQ:QURE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
It's been a good week for uniQure N.V. (NASDAQ:QURE) shareholders, because the company has just released its latest quarterly results, and the shares gained 4.5% to US$4.89. Revenues of US$8.5m
Stifel Nicolaus Sticks to Its Buy Rating for UniQure (QURE)
UniQure Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
UniQure Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
HC Wainwright & Co. : The UniQure (QURE.US) rating was reaffirmed and adjusted from buy to buy, and the target price was $25.00.
HC Wainwright & Co. : The UniQure (QURE.US) rating was reaffirmed and adjusted from buy to buy, and the target price was $25.00.
HC Wainwright & Co. Reiterates Buy on UniQure, Maintains $25 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates uniQure with a Buy and maintains $25 price target.
Mizuho Adjusts UniQure's Price Target to $6 From $7, Keeps Neutral Rating
Mizuho Adjusts uniQure's Price Target to $6 From $7, Keeps Neutral Rating.
UniQure Price Target Cut to $6.00/Share From $7.00 by Mizuho
UniQure Price Target Cut to $6.00/Share From $7.00 by Mizuho
Mizuho Maintains Neutral on UniQure, Lowers Price Target to $6
Mizuho analyst Uy Ear maintains uniQure (NASDAQ:QURE) with a Neutral and lowers the price target from $7 to $6.
UniQure (QURE.US): The 2024 Q1 financial report achieved revenue of US$8.485 million, with a previous value of US$5.325 million and an expected value of US$6.23 million; earnings per share were -1.36 USD, previous value of -1.63 USD, and expected value of
UniQure (QURE.US): The 2024 Q1 financial report achieved revenue of US$8.485 million, with a previous value of US$5.325 million and an expected value of US$6.23 million; earnings per share were -1.36 USD, previous value of -1.63 USD, and expected value of -1.33 USD.
uniQure NV | 10-Q: Quarterly report
Earnings Flash (QURE) UNIQURE Reports Q1 Revenue $8.5M
07:27 AM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (QURE) UNIQURE Reports Q1 Revenue $8.5M
UniQure Held Cash and Cash Equivalents and Investment Securities of $555.7M at March 31 >QURE
UniQure Held Cash and Cash Equivalents and Investment Securities of $555.7M at March 31 >QURE
UniQure Expects Cash, Cash Equivalents and Investment Securities Will Fund Ops Into the 2Q of 2027 >QURE
UniQure Expects Cash, Cash Equivalents and Investment Securities Will Fund Ops Into the 2Q of 2027 >QURE
UniQure Comprehensive Review of Ops and Options to Reduce Expenses Underway and Expected to Be Completed in Mid-2024 >QURE
UniQure Comprehensive Review of Ops and Options to Reduce Expenses Underway and Expected to Be Completed in Mid-2024 >QURE